AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 22 min read$AXSM

Axsome (AXSM) Q3 2026 Earnings Call Transcript

Axsome (AXSM) reported Q3 2026 revenue of $260M, up 52% YoY. AUVELITY sales grew 53% YoY to $208M, while SUNOSI revenue increased 47% YoY to $48.2M. Net loss narrowed to $12.9M from $47.2M YoY. The company highlighted strong prescription growth for AUVELITY, particularly in Alzheimer's agitation and major depressive disorder indications, and expects continued momentum. SYMBRAVO sales also grew 88% YoY to $3.9M. The company maintains a strong cash position and anticipates cash flow positivity.

Original reporting
finance.yahoo.com
Published Nov 2, 2026, 4:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 5:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Axsome (AXSM) Q3 2026 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$AXSMBullishMed
01

Why it matters

The earnings beat and narrowing loss are likely to lift the stock, though product discount levels remain a risk.

02

Market read

First‑time earnings disclosure with material financial improvements, relevant for biotech traders.

03

What to watch

High discount rates on products may pressure margins in later quarters.

Relevance 8/10Novelty 8/10Timing: after‑hours earnings release

Background

Axsome Therapeutics provided its Q3 2026 earnings call, highlighting revenue growth and loss reduction.

Company-level read

Ticker impact

$AXSMBullishHigh confidence
Context

Q3 2026 earnings call disclosed $260M revenue, 52% YoY growth, net loss narrowed to $12.9M, and strong product sales.

Expected impact

likely upward pressure as market prices in the revenue beat and loss improvement

Evidence & confidence

Revenue accelerated 52% YoY and net loss fell dramatically, indicating improved operating leverage.

Market effects

Sector

Boosts biotech sector sentiment on strong neurology product performance.

Regional

Positive for US‑listed biotech stocks.

Global

Limited to investors focused on neuroscience therapeutics.

Counterpoint

What could challenge this read

If guidance for Q4 is weak, the rally could be short‑lived.

Key entities

  • Company
    Axsome Therapeutics

    Biopharma developing neurology drugs.

Read at source← All news

StoryAxsome reports strong Q3 growth as AUVELITY sales accelerate

Also covered by

4 outlets

Related articles

NOV 2
$AXSMMedAI 8/10

Axsome Therapeutics, Inc. Q3 2026 Earnings Call Summary

Axsome Therapeutics reported Q3 2026 revenue growth of 52% YoY, driven by AUVELITY's performance in MDD and ADA, with total revenue surpassing $1B annually. Net loss narrowed to $12.9M due to operating leverage. AUVELITY saw sequential growth, with primary care prescribers being a key driver. The company maintained a gross margin in the low to mid-90% range. Management expects continued growth and sufficient cash to reach cash flow positivity.

finance.yahoo.com2 min
NOV 2
$AXSMMed

What Axsome Therapeutics (AXSM) Said on Its Q3 Earnings Call

Axsome Therapeutics reported Q3 earnings, with R&D expenses rising to $50.6M and SG&A to $203.1M. AUVELITY prescriptions grew 40% YoY, while SYMBRAVO and SUNOSI also saw increases. The company expects cash to fund operations until cash-flow positivity. Axsome outlined 2027 milestones, including FDA review of AXS-12 and trials for AXS-05, solriamfetol, and AXS-20.

finance.yahoo.com2 min